Vastarel MR

Vastarel MR





Concise Prescribing Info
Add-on therapy for the symptomatic treatment of patients w/ stable angina pectoris who are inadequately controlled by or intolerant to 1st-line antianginal therapies. Adjuvant symptomatic treatment for vertigo & tinnitus (noises detected by the ear: Whistling, buzzing, which do not correspond to any exterior sounds). Adjuvant treatment of visual disorders of a circulatory origin.
Dosage/Direction for Use
1 tab bid ie, in the morning & evening. Moderate renal impairment (CrCl 30-60 mL/min) & elderly 1 tab in the morning. Assess benefit of treatment after 3 mth & discontinue if there is no treatment response.
Should be taken with food: Swallow whole, do not chew/crush.
Hypersensitivity. Parkinsons disease, parkinsonian symptoms, tremors, restless leg syndrome, other related movement disorders, severe renal impairment (CrCl <30 mL/min).
Special Precautions
Not a currative treatment for angina attacks; not indicated as an initial treatment for unstable angina or MI; not for pre-hospital phase or during the 1st days of hospitalization. Reevaluate coronaropathy & consider adaptation of the treatment in the event of an angina attack. May cause or worsen parkinsonian symptoms (tremor, akinesia, hypertonia), which should be regularly investigated, especially in elderly patients. Falls related to gait instability or hypotension may occur especially in patients taking antihypertensive treatment. Caution in driving & use of machinery because dizziness & drowsiness have been observed. Pregnancy (avoid use) & lactation (should not be used).
Adverse Reactions
Dizziness, headache, abdominal pain, diarrhoea, dyspepsia, nausea, vomiting, rash, pruritus, urticaria, asthenia. Palpitations, extrasystoles, tachycardia, arterial hypotension, orthostatic hypotension that may be associated w/ malaise, dizziness or fall particularly in patients taking antihypertensives, flushing. Parkinsonian symptoms (tremor, akinesia, hypertonia), gait instability, restless leg syndrome, other related movement disorders (usually reversible after treatment discontinuation), sleep disorders (insomnia, drowsiness), vertigo, constipation, acute generalized exanthematous pustulosis), angioedema, agranulocytosis, thrombocytopenia, thrombocytopenic purpura, hepatitis.
ATC Classification
C01EB15 - trimetazidine ; Belongs to the class of other cardiac preparations.
Vastarel MR tab 35 mg
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in